Exclusive Investor Access to Startups with Real Potential - Only the Top 5% Qualify
We simplify the path to discovering and funding high-potential companies by identifying, vetting, and presenting only the strongest companies—giving investors a competitive advantage while saving time and focusing on the best opportunities.
Found a Company You Like? Request More Information
We Cut Through the Clutter So You Don’t Have To
Our role is to simplify venture investing by refining opportunities and giving you direct access to structured, and investment-ready companies.
—So you don’t have to sift through thousands of deals, network endlessly and meet hundreds of unqualified founders with us.
We’ve already done that, so you can focus on engaging with the best founders and making strategic decisions.
the process
1.
Explore Investment Opportunities
Review the companies listed on our Investor Portal
2.
Request More Information & Meet the Founders
Found a company that interests you? Request detailed investment materials and get direct access to startup founders through one-on-one meetings
3.
Close the Deal Efficiently
We facilitate a structured, efficient process to ensure smooth deal execution
+
Didn’t Find What You’re Looking For?
Let us know your investment criteria, and you’ll be the first to know when a relevant opportunity arises. We only send highly targeted opportunities that match your interests—no spam, no irrelevant deals.
Explore the Companies by Categories
Featured
BT759112
Transforming the future of aging and neurodegenerative disease treatment by developing gene therapies that restore youthful cellular function. Unlike conventional treatments that only manage symptoms, its tissue-specific gene therapies use partial cellular reprogramming to reset gene expression, directly reversing the biological processes that drive Alzheimer’s and other age-related diseases.
With a $550B market opportunity, an aging global population, and growing demand for disease-modifying treatments, the company is positioned at the forefront of the longevity and regenerative medicine revolution. Its breakthrough therapies have demonstrated significant cognitive restoration in preclinical models, offering a potentially curative approach to neurodegeneration—a massive unmet need in the healthcare industry.
Backed by exclusive partnerships with world-renowned researchers, a strong intellectual property portfolio, and a clear regulatory path toward clinical trials, the company is raising $10M to advance IND-enabling studies, GMP manufacturing, and further pipeline development. This is a rare opportunity to invest early in a high-impact biotech with first-mover advantage in a trillion-dollar industry.
BT457321
Transforming cancer treatment by introducing a non-invasive, AI-powered therapy that offers a breakthrough alternative to traditional chemotherapy and radiation. By leveraging oxygen therapy, peptides, IV-based treatments, and cutting-edge AI diagnostics, the company provides a painless, highly effective cancer treatment with a 70% success rate. Unlike conventional therapies that cause debilitating side effects, this approach is designed to enhance patient outcomes, improve quality of life, and make advanced cancer care more accessible.
With a $280B market opportunity, the oncology sector is rapidly shifting toward personalized, data-driven treatments, and this company is at the forefront of that transformation. Its AI-powered precision medicine platform enables early detection, tailored treatment plans, and scalable telehealth integration, making it a first-mover in a fast-growing market.
The company has already secured early traction with hospital partnerships and is positioned for rapid expansion. Now raising $2M to scale operations, refine its AI diagnostics, and accelerate market adoption, this is a unique opportunity to invest in the future of cancer care—an innovative, high-growth biotech that is redefining how cancer is treated worldwide.
BT275916
Chronic kidney disease is a $95B+ market with limited treatment options, and current therapies fail to address the root cause—cellular aging. This company is solving this with an AI-driven drug discovery platform that develops safer, more effective molecules to clear senescent kidney cells and reverse disease progression.
Unlike competitors struggling with off-target toxicity, its proprietary AI/ML-designed molecules enhance safety, metabolism, and bioavailability, dramatically increasing clinical success rates. With exclusive partnerships, a strong patent portfolio, and successful preclinical results in reversing disease progression in models, the company is positioned as the first to truly halt and reverse kidney disease at a cellular level.
Currently raising funds to advance IND-enabling studies and prepare for clinical trials, this is an opportunity to invest early in a biotech with massive acquisition potential in a billion-dollar market underserved by Big Pharma.
BT945680
The diagnostics industry is overdue for disruption, with outdated and inefficient testing methods limiting real-time treatment optimization. This company has developed a revolutionary biosensor platform that enables rapid, scalable, and highly specific drug and biomarker detection, dramatically improving diagnostics for metabolic health, chronic pain, and impairment testing.
Unlike traditional diagnostics that rely on costly, slow, and often imprecise methods, this company’s yeast-based receptor-binding assays use AI-enhanced biosensors to detect active drug metabolites and physiological responses in real-time—transforming how treatments are prescribed, optimized, and monitored.
With strong intellectual property, partnerships with leading research institutions, and a clear path to commercialization across multiple billion-dollar markets, the company is currently raising funds to accelerate regulatory approvals and market entry. This is a rare opportunity to invest early in a company positioned to redefine diagnostic precision across multiple industries.
MD248600
The $10.1B surgical robotics and guidance market is rapidly growing, yet surgeons still rely on limited visualization, manual navigation, and subjective decision-making, increasing the risk of complications and reoperations. This company is transforming the operating room with an AI-powered surgical guidance system that integrates real-time 3D mapping, advanced tissue recognition, and precision-enhancing automation to improve accuracy, efficiency, and patient outcomes.
Unlike traditional laparoscopic and robotic systems that offer limited intraoperative insights, this next-generation platform provides real-time AI-driven support, allowing surgeons to visualize critical structures, anticipate complications, and enhance surgical precision—drastically reducing the need for revisions and optimizing healthcare costs. With exclusive IP, partnerships with top-tier medical institutions, and a first-mover advantage in AI-assisted surgery, the company is positioned to disrupt the field of minimally invasive procedures.
Currently raising $3M to finalize product development, conduct hospital testing, and secure FDA clearance, this is a rare opportunity to invest in the future of AI-driven surgical innovation.
Request Exclusive Deal Access
Looking for something specific? Tell us your investment criteria, and we’ll notify you the moment a matching opportunity arises—only relevant and vetted deals, no unnecessary messages. You also have the opportunity to book a call with us at the end of the form.
Investment Criteria FormHow We Find and Vet companies
We believe that the best opportunities don’t come from mass outreach or cold deal sourcing. Instead, we rely on a high-quality, network-driven approach that ensures every startup we present has been sourced and vetted by experienced industry professionals.
A Network of Trusted Venture Partners
We work with a large network of venture partners—industry experts and veterans, successful founders, key decision-makers at investment firms, and investors—who consistently source and refer high-potential startups.
Why This Matters:
→ These individuals have deep industry knowledge and understand what makes a startup successful.
→ They meet founders in person, attend events, and discover deals before they hit the mainstream.
→ They only introduce startups they truly believe in, filtering out others before they reach our vetting stage.
A Rigorous Vetting Process
In the next step we conduct a thorough evaluation to determine if they meet our high standards.
What This Includes:
→ Multiple Rounds of Interviews – We engage with founders to understand their vision, execution capability, and industry expertise.
→ Data Collection & Analysis – We gather all key company information and analyze their model.
At the heart of our vetting process is the founder.
→ A bad founder can ruin a good company, no matter how great the product or market is.
→ A great founder can turn a struggling company into a success through adaptability, vision, and execution.
That’s why we place heavy emphasis on founder quality and leadership ability when selecting startups.
Structured, High-Quality Investment Materials
Once a startup passes our vetting process, we prepare investor briefs and structured materials to ensure you materials to make an informed decision.
This Includes:
→ Detailed company profiles with key information - since pitch decks many times miss relevant details.
→ Investment materials designed to make evaluating opportunities more efficient.
→ Direct access to founders for deeper discussions and strategic alignment.
We only work with founders who are serious about fundraising. If a startup delays the process, or lacks the basic information needed for a proper data room, it’s a clear red flag. We don’t waste time on unprepared founders—if they can’t organize their own business data, they aren’t ready for investment.
Continuous Monitoring & Deal Flow Optimization
We don’t just vet startups once and forget about them—we continuously monitor our portfolio, track their progress, and adjust our deal flow to align with investor demand.
Why This Matters:
→ Startups evolve quickly, and we ensure investors have access to the most updated company insights.
→ Dynamic deal flow – If market trends shift or investor demand evolves, we refine our pipeline to ensure relevant, high-value opportunities.
→ Strict quality control – If a startup fails to show meaningful traction or stagnates over time, we stop working with them, ensuring that only the most promising opportunities remain available.
By constantly evaluating startup performance and removing underperforming companies, we ensure that every opportunity presented stays aligned with high investor expectations.
what we solve
Deal Fatigue – Too Many Weak Deals, Not Enough Time
There’s no shortage of startups looking for funding, but most aren’t worth the time. Going through thousands of decks, reviewing unstructured information, and sitting through meetings with startups that aren’t ready for investment is exhausting.
We eliminate this problem by refining deal flow—curating only the strongest, most investment-ready opportunities so that every deal you see is worth your time.
Unstructured & Incomplete Investment Data
It’s hard to make smart investment decisions when the information is unclear. Too many startups present vague projections, incomplete financials, and confusing business models, making it difficult to compare opportunities and assess risk.
We structure every opportunity with clear, concise investment materials—so that every deal is easy to analyze and decision-ready.
Unqualified Founders & Wasted Meetings
Meeting with founders who aren’t prepared, don’t understand funding dynamics, or can’t answer key investment questions is a waste of time.
Every startup we present has been vetted—ensuring that only serious, investment-ready founders with solid business fundamentals make it through. No more wasted meetings, just high-quality investment discussions.
Limited Access to High-Quality, Exclusive Deals
The best opportunities often don’t make it to public deal platforms. Getting access to promising startups early—before they raise from larger VC firms—can make all the difference in securing the best returns.
We connect you to high-potential startups early, before they hit mainstream investor pipelines. Gain access to valuable opportunities before the market catches on.